Variables | Infection (n = 54) | No infection (n = 44) | p | |
Gender (%) | ||||
Women | 45 (83.3%) | 36 (81.8%) | 0.844 | |
Men | 9 (16.7%) | 8 (18.2%) | ||
Age groups (years) | ||||
<20 | 5 (9.3%) | 3 (6.8%) | 0.365 | |
20 - 40 | 35 (64.8%) | 25 (56.8%) | ||
41 - 60 | 14 (25.9%) | 14 (31.8%) | ||
>60 | 0 (0%) | 2 (4.5%) | ||
Duration of follow-up (months) | 28.72 ± 20.53 | 21.32 ± 19.70 | 0.074 | |
Serum creatinine (mg/l) | 22.55 ± 29.78 | 11.88 ± 11.20 | 0.027 | |
Renal failure (%) | 21 (38.9%) | 6 (13.6%) | 0.005 | |
Nephrotic syndrome (%) | 35 (64.8%) | 22 (50.0%) | 0.139 | |
Leucopenia (%) | 4 (7.4%) | 6 (13.6%) | 0.248 | |
Lymphopenia (%) | 21 (38.9%) | 19 (43.2%) | 0.667 | |
ANA (%) | 27 (93.1%) | 24 (92.3%) | 0.652 | |
Anti-DNA antibodies (%) | 16 (64.0%) | 17 (68.0%) | 0.765 | |
C3 hypocomplementemia (%) | 4 (57.1%) | 1 (14.3%) | 0.133 | |
C4 hypocomplementemia (%) | 4 (57.1%) | 2 (28.6%) | 0.296 | |
Proliferatives classes (%) | 37 (68.5%) | 14 (31.8%) | 0.001 | |
HCQ (%) | 44 (81.5%) | 38 (86.4%) | 0.515 | |
MTP (%) | 40 (74.1%) | 18 (40.9%) | 0.001 | |
Prednisone (%) | 54 (100.0%) | 40 (90.9%) | 0.038 | |
MMF (%) | 25 (46.3%) | 13 (29.5%) | 0.090 | |
CYC (%) | 19 (35.2%) | 8 (18.2%) | 0.061 | |
AZA (%) | 19 (35.2%) | 8 (18.2%) | 0.061 |